Table of Contents
- FDA and Global Regulations on Stem Cell Therapy
- Understanding FDA Regulatory Guidelines
- FDA Approval Process for Stem Cell Therapies
- FDA-Approved Stem Cell Products
- What the Approval Does Not Mean
- Investigational New Drug (IND) Policy for Stem Cell Use
- How Do Stem Cell Regulations Differ Around the World?
- Looking Ahead
- Frequently Asked Questions
- Reference Links
FDA regulation does not mean that every stem cell product is FDA-approved. The FDA applies different regulatory requirements depending on the product and its intended use. FDA approval, where applicable, applies to a specific product and approved use after the relevant requirements have been met. For patients seeking to understand the difference between regulation, clinical investigation, and FDA approval is important before considering any stem cell-based approach.Β
Key Takeaways
- FDA regulation does not mean that every stem cell therapy is FDA-approved.
- FDA approval applies to a specific product and its intended use, based on the applicable regulatory requirements and evidence.
- Some investigational stem cell products may require an Investigational New Drug (IND) application before clinical studies can proceed.
- The regulatory status of stem cell therapies differs between countries, so approval or authorisation in one country does not automatically apply elsewhere.
- Patients should distinguish between approved, investigational, and unapproved stem cell products before making healthcare decisions.
FDA and Global Regulations on Stem Cell Therapy
Patients researching stem cell-based approaches can encounter very different claims online. One source may describe the stem cell-based approach as approved for every condition, while another may describe a similar approach as investigational. For a patient trying to understand what this cell-based approach actually offers, and the level of evidence available, these differences can be confusing.Β
This is why regulations exist to help patients determine how stem cell-based approaches and products are researched, evaluated, and made available for specific conditions. Although regulatory systems differ between countries, terms such as FDA-approved, investigational, and regulated do not mean the same.Β
Understanding these distinctions can help patients look beyond promotional claims and make more informed decisions about stem cell-based approaches.Β
Understanding FDA Regulatory Guidelines
The FDAβs regulatory framework for stem cells and cellular products depends on the type of approach, how it is processed, and its purpose. These factors help scientists determine which regulatory requirements may apply.Β
| Regulatory Term | What It Means | What Patients Should Understand |
| Regulated | The product or activity falls under an applicable FDA regulatory framework.Β | Approaches under regulation do not automatically mean it’s FDA-approved.Β |
| Investigational | A product or approach is being studied under a clinical investigation to evaluate questions such as safety and effectiveness. | Being investigated does not mean the product has been proven effective or approved in general.Β |
| FDA-Approved | The FDA has approved a specific product for a specific intended use after reviewing the applicable evidence and requirements. | Approval applies to that particular product and approved use, not to all stem cell therapies. |
These terms are not interchangeable. When discussing the regulatory status of a stem cell product, one must always have in mind the particular product and use of that product.
FDA Approval Process for Stem Cell Therapies
FDA approval involves reviewing a specific product and its proposed intended use under the applicable regulatory pathway. Depending on the product and development pathway, evidence from preclinical studies and clinical investigations may be submitted for regulatory review.
This process usually goes through the following stages:
- Preclinical Studies: Scientists examine the product through laboratory and, if necessary, animal studies in order to learn more about its biological effects and possible safety.
- Clinical Testing: If the product is being tested on humans, clinical studies will be performed to determine the safety and efficacy of the product for its intended use.
- FDA Review: The scientific and clinical evidence provided is reviewed under the relevant regulatory process.
- Marketing Approval: If the product satisfies the requirements under the relevant regulation and the scientific evidence indicates the use of the product, then the FDA may approve it.
Although an important difference is that clinical investigation does not equal FDA approval. A stem cell product can be studied in humans while its safety and effectiveness still need further evaluation.Β
FDA-Approved Stem Cell Products
Currently, the FDA states only that the stem cell products approved in the United States consist of blood-forming stem cells, also known as hematopoietic progenitor cells, usually derived from umbilical cord blood. However, their approval is limited to specific uses involving the hematopoietic system.Β
What the FDA Approval Covers
- Product Type: Hematopoietic Progenitor Cells obtained from umbilical cord blood.
- Approved Use: Specific uses involving hematopoietic progenitor cells derived from umbilical cord blood for disorders affecting the hematopoietic system.
- Product-Specific Designation: The approval granted by the FDA is product-specific and not related to stem cell therapy in general.
What the Approval Does Not Mean
- It does not mean all stem cell products have received FDA approval.
- It does not imply FDA approval for unrelated medical indications or applications.
- A stem cell product under investigation in a clinical trial does not automatically mean the product has FDA approval for marketing.
- The FDA has noted that currently there are no FDA-approved exosome products.
As far as patients are concerned, the key point to understand is that FDA approval refers to a particular product used for an approved indication. This means that claims about βFDA-approved stem cell therapyβ must be verified.
Investigational New Drug (IND) Policy for Stem Cell Use
An Investigational New Drug (IND) application is part of the FDA regulatory process for certain investigational drugs and biological products being studied in humans. It provides the FDA with information about the product, its manufacturing, preclinical data, and proposed clinical investigation.Β It assists the FDA in getting information regarding the product, manufacturer, preclinical data, and clinical trial plans.
For patients, the most important distinction is:
- IND: Permits an applicable investigational product to go forward with its clinical investigation process.
- FDA Approval: Indicates that the FDA has approved a particular product for a certain purpose based on a review of the applicable facts and criteria.
An IND does not indicate the approval of the stem cell product by the FDA or its efficacy. An Investigational New Drug only implies that the product is being studied within the relevant regulations.
How Do Stem Cell Regulations Differ Around the World?
There is no standard global regulatory framework for stem cell research and products. Some countries use different regulatory authorities, classifications, and approval pathways, although patient safety, product quality, level of clinical evidence available, and research supervision are common concerns.Β
| Jurisdiction | Regulatory Framework | What Patient Should Know |
| United States | Food and Drug Administration (FDA) regulatory framework for cellular or tissue-based approaches or products | The regulatory requirements for stem cell products may vary from one type to another according to several aspects, including their nature, manufacturing process, and end-use application. |
| European Union | Advanced Therapy Medicinal Products (ATMP) framework | Certain cell-based products are regulated as advanced therapy medicinal products, with specific needs for development and marketing authorisation.Β |
| India | ICMR/DBT guidelines and applicable regulatory frameworkΒ | Stem cell research and clinical use are governed through national guidelines and applicable regulatory oversight. |
| CanadaΒ | Health Canada regulatory framework | There are certain federal requirements for cell therapy products as well as specific federal requirements for investigational cell therapy products. |
| Australia | Therapeutic Goods Administration (TGA) | Products of human cells and tissues are regulated through the proper pathway based on the risk related to their use. |
Understanding these differences matters for international patients, as regulatory approval in one country does not necessarily mean similar approval in another country.Β
These differences mean that the regulatory status of a stem cell product should always be checked within the country where it is being developed, studied, or offered.
Looking Ahead
Stem cell regulation is still evolving as scientists, regulators, and healthcare organisations seek to assess new cellular therapies. On the other hand, there are differences in regulatory systems from nation to nation that make information from abroad hard to comprehend for patients.
For patients interested in pursuing the treatment modality with the help of stem cells, knowledge of the exact product, usage, evidence, and regulatory approval is more helpful compared to generic terms like FDA-approved and internationally approved.Β
At Stem Cell Care India, patients can begin with a medical discussion about their individual situation and the relevant regulatory considerations before making decisions about a stem cell-based approach.
Frequently Asked Questions
Q1. Does FDA registration mean that a stem cell product is FDA-approved?
No. Being registered or listed with the FDA does not necessarily mean that a stem cell product has been approved for marketing. Patients should check the specific approaches or products, their intended use, and their actual regulatory status before considering it.Β
Q2. Does an IND mean that a stem cell therapy is proven to work?
No. An Investigational New Drug (IND) allows only an applicable investigational product to be investigated in people under the FDAβs regulatory process. It does not mean the approach or product has been approved or that its effectiveness has already been established.Β
Q3. Does FDA approval in the United States apply to other countries?
No. FDA approval only covers the regulatory system in the United States. Every country has its own set of regulations, and thus the approval of a particular product has to be assessed separately within each country.
Q4. Are all stem cell products FDA-approved?
No. FDA approval covers only certain specific products that are approved for certain applications. According to the FDA, the stem cell products that are approved include those that have blood-forming stem cells obtained from umbilical cord blood.
Q5. Can international patients consult Stem Cell Care India before travelling for stem cell therapy?
Yes. International patients can share relevant medical information with Stem Cell Care India for an initial medical discussion before making travel plans. The relevance of any stem cell-based approach depends on the individual case, available evidence, and applicable regulatory considerations.
Q6. How can patients check the regulatory status of a stem cell product?
The patient must not go by any marketing claims, such as FDA-approved, but find out more details regarding the product and its intended use. Consultation with a healthcare professional may also be helpful.
Reference Links
(1) U.S. Food and Drug Administration (FDA). (2020). Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.
(2) U.S. Food and Drug Administration (FDA). (2021). Important Patient and Consumer Information About Regenerative Medicine Therapies.
(3) U.S. Food and Drug Administration (FDA). (2026). Approved Cellular and Gene Therapy Products.
(4) Indian Council of Medical Research (ICMR) & Department of Biotechnology (DBT). (2017). National Guidelines for Stem Cell Research.
(5) Indian Council of Medical Research (ICMR). (2021). Evidence-Based Status of Stem Cell Therapy for Human Diseases.
ICMR Stem Cell Guidelines and Evidence-Based Resources
Medical Disclaimer
This blog is for educational and informational purposes only and does not constitute medical advice or a recommendation for any stem cell therapy. Regulatory status, clinical evidence, and suitability can vary by product, indication, and country. Patients should consult a qualified healthcare professional before making decisions about any stem cell-based approach.
